Breaking News

Head and Neck Cancer Study Progresses in Australia

January 7, 2021 • 3:42 am CST
(Vax Before Cancer)

Australia based Immutep Limited reported on January 6, 2021, it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study. This completes recruitment for Part C of the trial, which evaluates 2nd line HNSCC patients being treated with Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with MSD’s KEYTRUDA® (pembrolizumab).

The Company expects to report more data from TACTI-002 in the first half of CY 2021.